Introduction
============

Gene expression in eukaryotic cells is a highly dynamic process, involving transcription, splicing, mRNA export, mRNA localization, mRNA stabilization, and translation. In mammals, a genome-wide study estimated that 40-50% of changes in gene expression in response to cellular signals occur at the level of mRNA stability [@B1]. The AU-rich elements (AREs) in mRNA 3′ untranslated regions (UTRs) are recognized by a subset of RNA-binding proteins that modulate RNA stability [@B2]. Tristetraprolin (TTP) proteins bind AREs and destabilize mRNA [@B3]. This family is comprised of three proteins in man and four in rodents [@B4], including TTP (also called TIS11, ZFP36, NUP475, or G0S24), TIS11b (ZFP36L1, ERF1, BRF1, or CMG1), TIS11d (ZFP36L2, ERF2, or BRF2), and the rodent-specific ZFP36L3 [@B5]. All TTP proteins have a highly conserved C3H tandem zinc finger (TZF) domain, which binds to AREs and promotes the deadenylation and destruction of ARE-containing target sequences [@B6],[@B7].

In macrophages, TTP affects inflammation by negatively regulating the expression of pro-inflammatory factors such as tumor necrosis factor (TNF) and granulocyte-macrophage colony-stimulating factor [@B8],[@B9]. In *Drosophila melanogaster*, there is only one protein in the TTP family, DTIS11. Expression levels of antimicrobial peptides are regulated by the effects of DTIS11 on mRNA stability [@B10],[@B11]. Biological function analyses have shown that overexpression of TTP family members induces apoptosis in a variety of cell lines, including HeLa, U20S, SAOS1, 3T3, and B cell lymphoma cells [@B12]-[@B14]. Both TTP and TIS11b target *cIAP2* mRNA to regulate apoptosis [@B15],[@B16].

Using systematic genomic approaches, several mRNA targets of TTP proteins have been identified [@B17]-[@B19]. The *Drosophila*ARE database (D-ARED) indicates that \~16% of *Drosophila* genes contain the mammalian ARE signature, an AUUUA pentamer within an AU-rich context [@B20]. In *Drosophila*, DTIS11 temporally regulates gene expression through ARE-mediated mRNA decay [@B20]. To better understand TTP function *in vivo*, we overexpressed TTP proteins in the fly retina. Strikingly, this resulted in a phenotype that was similar to *eyes absent (eya)*loss of function. We further demonstrated that *eya* mRNA is a TTP binding target, and that *eya* mRNA is downregulated in response to TTP *in vivo*. We performed similar analyses in MCF7 cells, a human breast cancer cell line, and found that TTP overexpression destabilized *EYA2* mRNA. These results suggest that the interaction between TTP proteins and *eya* mRNA is a conserved regulatory mechanism that functions in a number of species and cell types.

Materials and methods
=====================

Plasmid constructs
------------------

*Drosophila* Gateway technology was used to generate plasmids for expressing tagged proteins. Mouse *TIS11b* was PCR amplified from cDNA derived from mouse RAW264.7 cells (forward primer 5′-CACCATGACCACCACCCTCGTGTC-3′, reverse primer 5′-TTAGTCATCTGAGATGGAGAG-3′). *DTIS11* was PCR amplified from *Drosophila* EST clone LD36337 (NHRI, Taiwan) (forward primer 5′-CACCATGTCTGCTGATATTCTGCAG-3′, reverse primer 5′-TTAGAGTCCCAAATTGGACTG-3′). PCR fragments were cloned into pENTR/D-TOPO vector (Invitrogen), confirmed by sequencing, and then transferred into *Drosophila*Gateway vectors pTFW and pTGW (gifts from Dr. M.-T. Su) *via* the Clonase II reaction (Invitrogen) to generate FLAG-tagged and GFP-tagged protein expression plasmids, respectively. The 3′ UTR of *eya* was PCR amplified from cDNA derived from fly heads (forward primer 5′-GAAAGGCCAAACTGTAAGGG-3′ \[hereafter, F primer\], reverse primer 5′-ATAGAGTGCGTTGCTGTTGG-3′ \[R primer\]). The resulting PCR fragment was ligated into pCRII-TOPO vector (Invitrogen), sequenced, and transferred into the 3′ end of pCMV-FLAG-Luciferase (Stratagene) for use in reporter assays. The 3′ UTR was separated into three fragments *via* PCR using the following primers: fragment 1, F primer and 5′-CGGGTACCGATCGTTGATTAGGTGTTTA-3′; fragment 2, 5′-GTAACAATTCTCGCACGAAG-3′ and 5′-CAGCCAGGATGCGTATC-3′; fragment 3, 5′-GAGAAGCGGAGCAAACAC-3′ and R primer. These fragments were ligated into the 3′ end of pCMV-FLAG-Luciferase. Coding sequences for mouse *TIS11b* and *TIS11d* were PCR amplified from cDNA derived from RAW264.7 cells that had been treated for 2 h with lipopolysaccharide. For *TIS11b*, forward and reverse primers were 5′- ATGACCACCACCCTCGTGTC-3′ and 5′-TTAGTCATCTGAGATGGAGAG-3′, respectively. For *TIS11d*, forward and reverse primers were 5′-ATGTCGACCACACTTCTGTCAC-3′ and 5′-TCAGTCGTCGGAGATGGAGAGGCG-3′, respectively. After sequencing, PCR fragments were subcloned into pCMV-Tag2B (Stratagene) and pEGFP-C2 (Clontech) for expression in mammalian cells. The cloning of mouse *TTP* has been described [@B21].

Site-directed mutagenesis
-------------------------

*DTIS11*^F158N^ and *mTTP*^F118N^ mutants were generated using the QuikChange site-directed mutagenesis kit (Stratagene). For these reactions, pTGW-DTIS11, pCMV-FLAG-DTIS11, and pCMV-FLAG-TTP were used as templates. Primers containing the desired mutation (underlined) were designed as follows: *DTIS11*, forward 5′-GAAGTGCCAG[AA]{.ul}CGCCCATGGA-3′ and reverse 5′-TCCATGGGCG[TT]{.ul}CTGGCACTTC-3′; *TTP*, forward 5′-CAAGTGCCAG[AA]{.ul}TGCTCACGGC-3′ and reverse 5′-GCCGTGAGCA[TT]{.ul}CTGGCACTTG-3′. All mutations were verified by sequencing.

Fly stocks
----------

*eya^2^*, *UAS-eya*, *UAS-GFP*, *tub-Gal80^ts^,* and *eq-Gal4*flies were from Y. Henry Sun (Institution of Molecular Biology \[IMB\], Academia Sinica, Taiwan); *UAS-Bcl*, *UAS-p53DN*, *UAS-p35*, *UAS-DIAP*, *UAS-mCD8GFP*, *Lz-Gal4*, and *GMR-Gal4*flies were from the Bloomington Stock Center; and *UAS-dTIS11^RNAi^* flies were obtained from the Vienna *Drosophila* RNAi Center. All fly stocks were maintained in 23º or 26ºC environmental insect culture chambers. The pUAS-FLAG-DTIS11, pUAS-FLAG-mTIS11b, pUAS-GFP-mTIS11b, pUAS-GFP-DTIS11, and pUAS-FLAG-DTIS11^F158N^ expression vectors were introduced into flies by traditional germ-line transformation at the IMB.

Cell culture
------------

*Drosophila* Schneider (S2) cells were grown at 25ºC in Schneider\'s *Drosophila* medium (Invitrogen) containing 10% heat-inactivated fetal bovine serum (FBS; Gibco-BRL). Human embryonic kidney (HEK) 293T cells were grown at 37ºC and 5% CO~2~ in DMEM supplemented with 3.7 g/L sodium bicarbonate and 10% FBS. Human breast cancer cells (MCF7) were cultured in MEM supplemented with 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 0.01 mg/mL bovine insulin, and 10% FBS. All three cell lines were purchased from Bioresource Collection and Research Center (BCRC, Taiwan)

Immunoblotting analysis
-----------------------

Fly heads or cultured cells were harvested and extracted in whole-cell extract buffer (25 mM HEPES, pH 7.5, 300 mM NaCl, 1.5 mM MgCl~2~, 0.2 mM EDTA, 0.1% (v/v) Triton X-100, 0.5 mM DTT). Whole-cell extracts (20 μg) were separated by SDS-PAGE and detected using anti-FLAG (Sigma-Aldrich), anti-GFP (GeneTex), anti-Eya (*Drosophila*Hybridoma Bank), or anti-γ-H2AX (Cell Signaling). The peroxidase labeled goat anti-rabbit or goat anti-mouse secondary antibody (KPL) in combination with Western Lightning- enhanced chemiluminescence substrate (PerkinElmer) were used for detection on X-ray film from FUJIFILM Corporation.

RNA immunoprecipitation (RNA-IP)
--------------------------------

Whole-cell extracts (300 μg) from control fly heads or fly heads expressing FLAG-mTIS11b were adjusted to 25 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM MgCl~2~, 0.2 mM EDTA, 0.1% (v/v) Triton X-100, 0.5 mM DTT, and 1 U/μL RNasin. Samples were pre-cleaned with protein A-Sepharose (Amersham Pharmacia) for 1 h. After centrifugation, anti-FLAG-Sepharose (Sigma-Aldrich) was added to the supernatants and rotated at 4ºC for 2 h. Beads were washed three times using NT2 buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM MgCl~2~, 0.05% NP-40) and then incubated with 100 μL NT2 buffer containing 5 U RNase-free DNase I (Ambion) for 15 min at 30ºC. Beads were washed once with NT2 buffer and then incubated in 100 μL NT2 buffer containing 0.1% SDS and 0.5 mg/mL proteinase K at 55ºC for 15 min. For RT-PCR, RNA was extracted with TRIzol (Invitrogen). cDNAs of interest were amplified using 4% of the RT reaction in a 20-µL PCR reaction containing 10 pmol forward and reverse primers, respectively: *eya*, 5′-CCTGGCTACAGATACGCTCG-3′ and 5′-TGGAGGTTACCAGCACGTTG-3′; *rp49*, 5′-GCGCACCAAGCACTTCATC-3′ and 5′-GTAAACGCGGTTCTGCATGAG-3′. PCR products were separated using 2% agarose gel electrophoresis. FLAG-tagged *TTP* and *TTP*^F118N^ were expressed in MCF7 cells, and whole-cell extracts were isolated to perform RNA-IP. After RNA isolation and reverse transcription, human *EYA2* and *β-actin* mRNA were detected by PCR using the following primers: *EYA2*, 5′-GGACAATGAGATTGAGCGTGT-3′ and 5′-ATGTGGGGTTGAGTAAGGAGT-3′; *β-actin*, 5′-GCACCAGGGCGTGATGG-3′ and 5′-GCCTCGGTCAGCAGCA-3′.

RNA pull-down analysis
----------------------

To overexpress mouse TTP family proteins and DTIS11, 1 × 10^7^ HEK293T cells were transfected with GFP-TTP, GFP-TIS11b, GFP-TIS11d, GFP-DTIS11, FLAG-DTIS11, or FLAG-DTIS11^F158N^ expression plasmid (10 μg) using calcium phosphate precipitation. Cytoplasmic extracts were prepared using hypotonic buffer (10 mM HEPES, pH 7.5, 10 mM potassium acetate, 1.5 mM MgCl~2~, 2.5 mM dithiothreitol, 0.05% NP-40, protease inhibitor cocktail (Sigma-Aldrich), and phosphatase inhibitors containing 0.01 M β-glycerol phosphate, 0.1 mM Na~2~MoO~4~, 0.1 mM Na~3~VO~4~, pH 10.0, and 0.01 M NaF). The potassium acetate concentration of the extracts was adjusted to 90 mM, and then 0.2 U/µL RNase inhibitor (Promega) and 0.1 µg/µL yeast tRNA (Ambion) were added. Extracts were incubated with 15 μL heparin-agarose (Sigma-Aldrich) at 4ºC for 15 min, and subsequently cleaned with 10 μL streptavidin-Sepharose (Invitrogen) for 1 h at 4ºC with rotation. *In vitro*-transcribed biotinylated ARE (4 µg) from the 3′ UTR of *eya*, *TTP*, *TNF*, or control *18S rRNA* (T7-MEGAshortscript, Ambion) was added to the supernatant, and the mixture was incubated for 1 h at 4ºC. The protein and biotinylated RNA complexes were recovered by addition of 10 μL streptavidin-Sepharose at 4ºC for 2 h with rotation. After washing four times with binding buffer (10 mM HEPES, pH 7.5, 90 mM potassium acetate, 1.5 mM MgCl~2~, 2.5 mM dithiothreitol, 0.05% NP-40, and protease and phosphatase inhibitor cocktails), pulled-down complexes were analyzed by immunoblotting using anti-FLAG.

Transfection and luciferase reporter analysis
---------------------------------------------

HEK293T cells were seeded into six-well plates at a density of 2 × 10^5^cells/well. The next day, cells were transfected using calcium phosphate precipitation (0.5 µg pCMV-FLAG-luciferase or pCMV-FLAG-luciferase-*eya*3′ UTR constructs, 0.01 µg pCMV-β-galactosidase, and indicated dosages of DTIS11 and DTIS11^F158N^ expression vectors). After 36 h, RNA was isolated for quantitative PCR analysis (described in next section), and cell lysates were collected for luciferase and β-galactosidase activity assays [@B22] and immunoblotting. To correct for variations in the transfection efficiency and expression level of each construct, luciferase assay values were divided by the β-galactosidase value and then normalized to the control group. Each treatment condition was performed in duplicate, and each experiment was repeated three times independently.

RNA isolation and quantitative PCR
----------------------------------

To examine endogenous *eya* mRNA expression, S2 cells were seeded into six-well plates at a density of 5 × 10^5^cells/well and transfected with 3 μg of pAC5.1-GFP, pAC5.1-GFP-DTIS11, or pAC5.1-GFP-DTIS11^F158N^ using Lipofectamine 2000 (Invitrogen). After 24 h, total RNA was collected using TRIzol. Total RNA (20 µg) was subsequently treated with TURBO DNase (Ambion) at 37ºC for 1 h, and then extracted using TRIzol. Total RNA (5 µg) was reverse-transcribed to cDNA in the presence of 0.5 μg oligo-dT primer using M-MLV reverse transcriptase (Promega). Quantitative real-time PCR was performed in a total volume of 20 µL with FastStart Universal PCR Master Mix (Roche) on an Applied Biosystems 7300 Real-Time PCR System. Reactions contained cDNA template plus forward and reverse primers for *eya* and*rp49*(0.4 µM each). Similar experiments were performed in MCF7 cells overexpressing TTP family proteins. In these experiments, PCR was carried out using human *EYA2* and *β*-*actin* primers. RNA from HEK293T cells (described above) was analyzed by PCR using luciferase primers (5′-ACAACACCCCAACATCTTCGA-3′ and 5′-CGTCTTTCCGTGCTCCAAAA-3′) and *β-galactosidase* primers (5′-GGATGTCGCTCCACAAGGTAA-3′ and 5′-CGGTTGCACTACGCGTACTGT-3′). Amplification conditions were 40 cycles of 95ºC for 15 s and 60ºC for 1 min. Results were analyzed using a mathematical ΔΔCt method.

MTS cell viability assay
------------------------

S2 cells or MCF7 cells were seeded into 96-well plates at a density of 1 × 10^4^ cells/well with 100 μL culture medium. They were transfected with 0.2 μg DNA using Lipofectamine 2000. After 2 days, 20 μL CellTiter 96 AQueous One Solution (Promega) was added to each well, and cells were incubated at 25º (S2 cells) or 37 ºC (MCF7 cells) for 2 h. Absorbance at 490 nm was recorded using a SpectraMax M2e Microplate Reader (Molecular Devices). Each treatment condition was performed in triplicate, and each experiment was repeated at least three times independently.

Determination of cell number in MCF7 cells
------------------------------------------

MCF7 cells were seeded into six-well plates at a density of 1 × 10^5^ cells/well and transfected with expression vectors for GFP-tagged TTP family proteins using Lipofectamine 2000. The medium was changed after 20 h transfection and cells were harvested after further 20 h. Cells were stained with trypan blue and counted in a Countess Automated Cell Counter (Invitrogen) following the manufacturer\'s instructions.

Statistical analysis
--------------------

Luciferase reporter activity and RNA, endogenous *eya*mRNA, and MTS cell survival assays were quantified using one-tailed Student\'s *t*-test.*Drosophila* eye size was analyzed using ImageJ and two-tailed Student\'s *t*-test.

Results
=======

Overexpression of TIS11 proteins result in a small eye phenotype
----------------------------------------------------------------

To investigate the biological function of TTP, we used the *Drosophila*genetic system to express both mouse and fly TIS11. Fig. [1](#F1){ref-type="fig"}A shows the amino acid sequences of DTIS11 and three mouse TTP family members. The proteins have highly conserved TZF domains, but variable N- and C-terminal sequences. GFP-tagged TTP, TIS11b, TIS11d, and DTIS11 were expressed in HEK293T cells and shown to bind the ARE from TNF using a pull-down assay (Fig. [1](#F1){ref-type="fig"}B). This indicates that DTIS11 and mouse TTP proteins have similar RNA-binding activity. Moreover, DTIS11 or mouse TIS11b expressed in the fly retina by specific *GMR*-Gal4 caused an eyes absent or small eye phenotype, respectively (Figs. [2](#F2){ref-type="fig"}A-C). When DTIS11 was expressed in the fly retina by a pigment cell driver, *Lz*-Gal4, the number of pigment cells was dramatically reduced and rhabdomere structure was disrupted (Fig. [2](#F2){ref-type="fig"}E).

The number of interommatidial cells is known to be precisely regulated by programmed cell death [@B23],[@B24]. The severe reduction in the number of interommatidial cells in this experiment implied that overexpression of DTIS11 induced apoptosis. To narrow down this apoptotic time window and to determine which developmental stage was most affected by DTIS11, we used a temperature-sensitive Gal4 repressor (Gal80^ts^) [@B25] to temporally regulate DTIS11 expression in the eye. When DTIS11 overexpression was initiated during pupal development, the eye phenotype was much milder than with the conventional *GMR-*Gal4, which drives constitutive expression from embryonic stages ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S1). Notably, when DTIS11 overexpression commenced at a late pupal stage (\~85% after puparium formation \[APF\]), numerous black spots---typically indicative of apoptosis---were present in the adult retina. Consistent with this observation, the DTIS11-induced small eye phenotype was partially rescued by two apoptosis inhibitors, *Drosophila* inhibitor of apoptosis (DIAP) and p35 ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S2).

Due to TTP family members belonging to RNA-binding proteins, we next tested whether the mRNA-binding capability of DTIS11 was required to cause eye deficits. To this end, we generated a transgenic fly, *UAS-DTIS11^F158N^*, expressing a protein in which the TZF RNA-binding domain, which is critical for TTP function [@B26], was mutated. Interestingly, eyes expressing DTIS11^F158N^ did not exhibit an eyes absent phenotype and were morphologically indistinguishable from wild type (Fig. [2](#F2){ref-type="fig"}D). Immunoblot analysis confirmed that DTIS11^F158N^ was indeed expressed (Fig. [2](#F2){ref-type="fig"}F). Although DTIS11^F158N^ was more abundantly expressed than wild-type DTIS11, it did not elicit an aberrant eye appearance without a functional RNA-binding domain. Taken together, our results show that overexpression of DTIS11 in the fly retina leads to eye defects, and that the RNA-binding activity of DTIS11 is required for this phenotype.

eya mRNA is a target of TTP proteins
------------------------------------

To determine the mechanism by which DTIS11 affects eye development, we attempted to identify its mRNA binding targets by performing RNA-IP. We took a candidate gene approach, concentrating on ARE-containing genes that play a role in apoptosis based on a search of D-ARED data [@B20]. However, the level of DTIS11 protein in the eye was too low for RNA-IP (Fig. [2](#F2){ref-type="fig"}F), likely because of the reduced amount of eye tissue. Thus, RNA-IP was performed using eyes expressing FLAG-tagged mTIS11b, which elicited a milder phenotype (Fig. [2](#F2){ref-type="fig"}C). Using FLAG-IP, RNA was isolated for reverse transcription followed by semi-quantitative PCR analysis ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S3). The candidate gene *eya* exhibited a reduction in mRNA and protein level in response to mTIS11b expression (Fig. [3](#F3){ref-type="fig"}A). Furthermore, *eya* mRNA and mTIS11b were present in the same complex (Fig. [3](#F3){ref-type="fig"}A). To confirm that endogenous Eya was downregulated spatially in the fly retina by overexpression of TIS11 proteins, we performed Eya antibody staining in eye imaginal discs. As previously reported [@B27],[@B28], we found endogenous Eya expressed primarily behind the morphogenetic furrow ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S4), where the *GMR*-Gal4 was specifically expressed. Subsequently, when we knocked down DTIS11 by *eq*-GAL4-driven RNAi, it resulted in Eya accumulation and expansion in the area before the morphogenetic furrow ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S5). Interestingly, the *eya* null phenotype is quite similar to that seen with DTIS11 overexpression [@B27] (Fig. [3](#F3){ref-type="fig"}B). In addition, *eya* overexpression was able to partially rescue the small eye phenotype caused by TIS11b (Figs. [3](#F3){ref-type="fig"}C and D). To rule out the possibility of unexpected effects on cell growth from *GMR*-Gal4 driving UAS-Eya, Eya was overexpressed alone in the fly retina. It did not result in an overgrown eye phenotype ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S6), clarifying that Eya overexpression indeed could rescue TIS11b mediated small eye phenotype. These results suggest that *eya* mRNA is a target of TIS11 proteins *in vivo*, and that downregulation of *eya* mRNA by DTIS11 or mTIS11b overexpression may result in the small eye phenotype.

Physical and functional interactions between DTIS11 and the 3′ UTR of eya
-------------------------------------------------------------------------

To characterize the interaction between *eya* and DTIS11, the ARE-containing 3′ UTR of *eya* mRNA was evaluated. The 3′ UTR was isolated and separated into three fragments for binding analyses (Fig. [4](#F4){ref-type="fig"}A). RNA pull-down experiments indicated that DTIS11 bound to the full-length *eya* 3′ UTR and to fragment 1 (the most proximal fragment to the coding sequence), but not to fragment 2 or 3 (Fig. [4](#F4){ref-type="fig"}B). As a positive control, we used the TTP ARE, a well-characterized ARE in the 3′ UTR of mouse TTP mRNA [@B22]. In addition, the DTIS11^F158N^ mutant did not bind the 3′ UTR of *eya*(Fig. [4](#F4){ref-type="fig"}B).

To carry out reporter assays, we cloned the full-length 3′ UTR and each fragment into the 3′ end of the luciferase gene. HEK293T cells were cotransfected with the luciferase-*eya* 3′ UTR reporter plasmid plus a FLAG-tagged DTIS11 expression plasmid, and luciferase activity was measured 24 h after transfection. DTIS11 protein levels are shown in the lower panel of Fig. [4](#F4){ref-type="fig"}C. Consistent with our RNA-protein interaction data, DTIS11 significantly reduced luciferase activity when the full-length 3′ UTR or fragment 1 was tested. Similar results were seen with TTP ARE. Downregulation of luciferase activity by DTIS11 was also reflected in decreased levels of luciferase mRNA (Fig. [4](#F4){ref-type="fig"}D). In contrast, DTIS11^F158N^did not affect luciferase activity or RNA expression (Figs. [4](#F4){ref-type="fig"}C and D). Although fragment 2 did not pull down DTIS11 protein (Fig. [4](#F4){ref-type="fig"}B), luciferase activity was attenuated by DTIS11 overexpression using this fragment (Fig. [4](#F4){ref-type="fig"}C). These results demonstrate that DTIS11 binds to the 3′ UTR of *eya* mRNA (specifically, fragment 1), thereby reducing *eya*expression.

DTIS11 downregulates eya expression and affects viability of S2 cells
---------------------------------------------------------------------

To further demonstrate the downregulation of *eya* mRNA expression by DTIS11, we transfected DTIS11 and DTIS11^F158N^ into *Drosophila* embryonic S2 cells. Total RNA was isolated and *eya*mRNA was detected by quantitative PCR. Compared to the empty vector and the RNA-binding mutant DTIS11^F158N^ as negative controls, DTIS11 overexpression significantly decreased *eya* mRNA levels (Fig. [5](#F5){ref-type="fig"}A, left panel). Immunoblotting revealed the levels of overexpressed GFP-tagged proteins (Fig. [5](#F5){ref-type="fig"}A, right panel). Moreover, data from MTS cell viability assays revealed that the viability of cells overexpressing DTIS11 was significantly reduced compared with vector or DTIS11^F158N^ controls (Fig. [5](#F5){ref-type="fig"}B). Given the low transfection efficiency of S2 cells with Lipofectamine (\<40%), dramatic decreases of *eya* expression and cell viability is unlikely. This indicates that DTIS11 may impair cell viability by destabilizing *eya* mRNA in S2 cells.

Overexpression of TTP proteins downregulates EYA2 mRNA levels in human breast cancer cells
------------------------------------------------------------------------------------------

We next asked whether the interactions between*eya* mRNA and DTIS11 were evolutionarily conserved. In the human genome, there are four *eya* homologs (*EYA1*-*4*), and each mRNA contains a long 3′ UTR (1905, 709, 4096, and 3314 bp, respectively) with putative AREs based on sequence analysis. Human *EYA2* is upregulated in the human breast cancer cell line MCF7 [@B29],[@B30]. We transiently overexpressed individual mouse TTP proteins in MCF7 cells and measured *EYA2* expression and cell viability. TTP, TIS11b, and TIS11d decreased *EYA2* mRNA levels, while the TTP^F118N^ mutant did not (Fig. [6](#F6){ref-type="fig"}A, top). Trypan blue staining showed that overexpression of wild-type TTP proteins caused a decrease in the number of live cells (Fig. [6](#F6){ref-type="fig"}A, middle). MTS cell viability analysis was shown in [Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S7A. To determine whether TTP could induce apoptosis in MCF7 cells, we performed immunoblotting for γ-H2AX (Ser139-phosphorylated histone protein H2AX), which is induced by loss of EYA and some apoptotic signals [@B31]-[@B33]. Compared to the vector and mutant TTP, overexpression of wild-type TTP increased the γ-H2AX signal ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S7B). Furthermore, TUNEL assays showed that wild-type TTP increased the apoptotic response ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S7C). To determine whether TTP downregulates *EYA2* mRNA levels by accelerating its decay, we measured *EYA2* mRNA stability using actinomycin D treatment to block RNA synthesis (Fig. [6](#F6){ref-type="fig"}B). These data revealed that *EYA2* mRNA decayed more rapidly in MCF7 cells expressing TTP than in MCF7 cells expressing GFP or TTP^F118N^. RNA-IP demonstrated that TTP, but not TTP^F118N^, was associated with *EYA2* mRNA (Fig. [6](#F6){ref-type="fig"}C). Collectively, these results demonstrate that TTP bound to and destabilized *EYA2* mRNA, and that overexpression of TTP proteins decreased viability in MCF7 cells.

Discussion
==========

In this study, we overexpressed DTIS11 in the *Drosophila* retina, resulting in a small eye phenotype due to programmed cell death. In contrast, a mutant DTIS11 in which the RNA-binding TZF domain had been mutated had virtually no effect on the eye. This suggests that RNA-binding activity is critical for DTIS11 function. Using RNA-IP, we identified a novel TIS11 target mRNA, *eya*. We demonstrated that DTIS11 physically interacted with the 3′ UTR of *eya*mRNA to reduce mRNA expression. Furthermore, decreased expression of *eya* was correlated with reduced cell viability in *Drosophila* S2 and human MCF7 cells. Together, these data indicate that *eya* mRNA is depleted when TIS11 levels are elevated. In addition, this interaction represents a regulatory mechanism that has been conserved during evolution.

The *eya* gene was first identified in *Drosophila*, where it functions to determine retinal cell fate [@B27]. *eya* mutations lead to an elevated rate of apoptosis in ommatidial precursor cells, preventing development of the compound eye [@B34],[@B35]. In vertebrates, four *eya* homologs have been identified, each containing an N-terminal transactivation domain and threonine phosphatase domain, and a C-terminal tyrosine phosphatase domain [@B36]. These proteins activate *c-myc* gene expression for cell proliferation [@B37], and regulate DNA repair via dephosphorylation of H2AX [@B31]. TTP mRNA and protein levels are significantly decreased in tumors of the thyroid, lung, ovary, uterus, and breast compared to non-transformed tissues [@B38],[@B39]. Restoring TTP expression in an aggressive tumor cell line suppresses cell proliferation and stimulates apoptosis [@B40]. In contrast, EYA levels are upregulated in a number of cancers, including EYA2 in ovarian and breast cancers [@B29], EYA1 in Wilms\' tumor [@B41], and EYA4 in malignant peripheral nerve sheath tumors [@B42]. Moreover, overexpression of EYA1, EYA2, or EYA3 increases proliferation, invasion, and transformation of breast cancer cells [@B43]. It appears, therefore, that TTPs and EYAs have inverse patterns of expression and functional effects in tumor cells. This is consistent with our observation that TTP overexpression reduced *EYA2* mRNA levels and cell viability. As such, TTP proteins may target *eya* mRNA to regulate cell survival. However, *eya*overexpression only partially rescues the small eye phenotype caused by mTIS11b. We also failed to rescue the DTIS11overexpression-induced eyes absent phenotype by coexpression of *eya*(data not shown). These suggest that other apoptosis-related genes, such as *diap1* and a gene encoding the eye-specific transcription factor*glass* [@B44] ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S3), or other unidentified ARE-containing mRNAs may also be targets of TIS11 proteins and contribute to the phenotypic outcome.

The 3′ UTR of *Drosophila eya* mRNA contains multiple AREs. To functionally characterize the 3′ UTR, we separated it into three fragments. Fragment 1 contains four AREs, and the other two contain one each. Fragment 1 bound most effectively to DTIS11. Although fragment 2 did not pull down TTP in biochemical experiments, it responded to DTIS11 expression *in vivo*. A similar effect was observed when TTP regulation of *VEGF* mRNA was examined [@B45]. In addition, several potential mRNA targets of TTP that were identified in a previous microarray experiment do not contain typical AREs [@B17],[@B18]. This suggests that TTP may regulate the stability of these mRNAs through a binding-independent mechanism. To determine whether TTP regulates *eya* mRNA stability in mammalian cells, we analyzed the mRNA sequences of four *eya* homologs. Each had a long 3′ UTR containing putative AREs and U-rich sequences. EYA2 is the predominant EYA family member in MCF7 cells [@B30]. RNA-IP analysis demonstrated that TTP associated with *EYA2* mRNA and destabilized it. This implies that overexpression of EYA2 in breast cancer MCF7 cells can be post-transcriptionally downregulated by TTP proteins. The detailed physical and functional interactions between TTP family members and human*EYA* mRNAs should be further characterized.

When the amino acid sequence of DTIS11 was compared with the mouse homologs TTP, TIS11b, and TIS11d, DTIS11 was most similar to TIS11b and TIS11d (Fig. [1](#F1){ref-type="fig"}A). These proteins share 90% amino acid identity within the TZF domain, but have quite divergent N- and C-terminal sequences. The TZF domain is responsible for RNA binding, whereas the N- and C-terminal regions recruit the mRNA decay machinery (e.g., deadenylase [@B46]-[@B48], 5′ mRNA decapping [@B49], and 3′ exosome [@B50] complexes). In our experiments, DTIS11 was able to downregulate ARE-mediated luciferase activity in HEK293T cells, indicating that interactions between TTP proteins and proteins involved in mRNA decay may have been evolutionarily conserved. Although overexpression of either TIS11b or DTIS11 disrupted *Drosophila* eye development, the effects seen with TIS11b were less dramatic. Thus, there may be slight differences in the way these two proteins interact with effector proteins. For example, the Cbl-interacting protein CIN85 interacts with the C terminus of human TTP but not with other protein family members [@B51]. It has also been reported that TTP, but not TIS11b, interacts with the Tax protein from human T lymphotropic virus 1 through its C-terminal domain [@B52].

Studies in animal model systems have demonstrated that TTP plays a critical role in the immune system, whereas TIS11b and TIS11d may function during embryonic development [@B53]-[@B55]. Although DTIS11 is most similar to TIS11b and TIS11d at the amino acid level, it is functionally most similar to TTP. For example, DTIS11 regulates the mRNA stability of anti-microbial peptides [@B10],[@B11]. Here, we have identified a novel mRNA target of DTIS11, *eya*, and provided*in vivo* evidence that DTIS11 regulates eye development by interacting with and destabilizing *eya* mRNA, especially during embryogenesis. These observations also suggest that this single gene in *Drosophila* may be responsible for functions that are carried out by multiple genes in mice and humans.
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**Comparison between *Drosophila* and mouse TTP family members.** (A) Amino acid sequences of *Drosophila* DTIS11 and mouse TTP family members. (B) HEK293T cells were transiently transfected with GFP vector or GFP-tagged TTP, TIS11b, TIS11d, or DTIS11 expression vectors. After 24 h, cytosolic extracts were isolated and incubated with biotinylated *TNF* ARE or control *18S* rRNA. The pulled down proteins were subjected to immunoblot analysis using anti-GFP.
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![**Overexpression of DTIS11 proteins in the *Drosophila* eye.**(A-D) Bright field images of fly retinas expressing TIS11 variants by *GMR*-Gal4. (A, control; B, *Drosophila* TIS11 \[DTIS11\]; C, murine TIS11b \[mTIS11b\]; D, RNA-binding domain mutant DTIS11^F158N^). (E) Use of the pigment cell driver *Lz*-Gal4 to express DTIS11 in retina. Pupal eyes (48 h APF) were dissected and labeled by immunohistochemistry (left, control; right, DTIS11 overexpression). Retinal pigment cells were revealed by anti-armadillo staining (green), and rhabdomere structure of photoreceptors was counterstained with phalloidin (red). Scale bar, 10 μm. (F) Immunoblot analysis of total protein from fly heads for expression of DTIS11 and DTIS11^F158N^.*w^1118^* was used as a non-transgenic control. Numbers below bands indicate amount of protein loaded.](ijbsv08p0606g03){#F2}

![**Identification of *eya* mRNA as a target of TIS11 proteins in *Drosophila*.** (A) Analysis of *eya* expression. Semi-quantitative RT-PCR determines the mRNA expression of *eya* (top) and *rp49* (middle), and the level of *eya* mRNA bound to FLAG-tagged TIS11b (bottom) in control and mouse TIS11b overexpression fly. Numbers indicate amount of RNA-IP reaction analyzed by quantitative PCR. Right panel is immunoblotting analysis with anti-Eya. (B) Eye phenotype resulting from DTIS11 overexpression was similar to the *eya* mutant. (C) Coexpression of *eya* with mTIS11b partially rescued the small eye phenotype caused by overexpression of mTIS11b alone. (D) Statistical analysis shows that *eya* significantly rescued the reduced eye size resulting from mTIS11b overexpression. *n* = 3; \**P =* 0.0048 by two-tailed Student\'s *t*-test.](ijbsv08p0606g04){#F3}

![**Physical and functional interactions between DTIS11 and 3′ UTR of*eya*mRNA.** (A) Nucleotide sequence of the 3′ UTR of *Drosophila eya* (GenBank accession no. NM_164693, nt 2511-3073) separated into three fragments (fragment 1, nt 2511-2730; fragment 2, nt 2731-2860; fragment 3, nt 2861-3073). AREs are indicated by bold text. (B) RNA pull-down assay using full-length (FL) *eya* 3\'UTR and *eya* 3\'UTR fragments (\#1, \#2, and \#3) with FLAG-tagged DTIS11 (WT) and DTIS11^F158N^ (F158N). *TTP* ARE and *18S* rRNA were used as positive and negative controls, respectively. The pulled down proteins were immunoblotted with anti-FLAG. (C-D) The luciferase gene was fused to full-length *eya* 3′ UTR or 3′ UTR fragments, and HEK293T cells were cotransfected with a luciferase plasmid and FLAG-DTIS11 or FLAG-DTIS11^F158N^ expression plasmids. A *TTP* ARE-containing luciferase plasmid served as a positive control. After 24 h, cell lysates were isolated for luciferase activity assays. Relative *eya*3′ UTR-mediated luciferase activity is presented as mean ± SD. \**P*\< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. The expression level of wild-type or mutant DTIS11 was determined by immunoblotting with anti-FLAG (the arrows indicate FLAG-luciferase signal) (C). (D) Quantitative PCR was used to determine full-length *eya* 3\'UTR-mediated luciferase mRNA expression. Expression data were normalized to *β-galactosidase* mRNA and are shown as mean ± SD. \**P*\< 0.05. Duplicate reactions were performed and each experiment was repeated three times.](ijbsv08p0606g05){#F4}

###### 

**Overexpression of DTIS11 in S2 cells.** (A) Overexpression of DTIS11 decreased *eya* mRNA expression in S2 cells. S2 cells were transfected with GFP-tagged DTIS11 (WT) or GFP-tagged DTIS11^F158N^ (F158N) expression plasmids. *eya* expression was determined by quantitative PCR and normalized to *rp49* as a negative control (\**P*\< 0.05, \*\**P* \< 0.01). Levels of GFP-tagged proteins were detected by immunoblotting with anti-GFP. (B) Cell viability analysis. S2 cells were seeded into 96-well plates and transiently transfected with GFP-tagged DTIS11 or DTIS11^F158N^ expression plasmids. After 2 days, cell viability was determined by MTS assay and normalized to vector control (\*\**P* \< 0.01, \*\*\**P* \< 0.001). Each treatment was performed in triplicate and the experiment was repeated five times.
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![**Overexpression of TTP proteins in MCF7 cells.**(A) TTP proteins downregulated human *EYA2* (*hEYA2*) expression and cell viability in MCF7 cells. MCF7 cells were transiently transfected with GFP vector or GFP-tagged TTP, TIS11b, TIS11d, or TTP^F118N^ expression vectors. After 40 h, *EYA2* expression was measured by quantitative PCR (top), cell viability was measured using trypan blue (middle), and immunoblotting was performed using anti-GFP (bottom). \**P*\< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. (B) Determination of *EYA2* mRNA stability. MCF7 cells were transiently transfected with GFP-TTP or GFP-TTP^F118N^expression vectors. A vector-only control was also included. After 40 h, cells were untreated or treated with 10 μg/ml actinomycin D (Act D) for 15 and 30 min. RNA was then isolated for quantitative PCR using *EYA2* and *β*-*actin* primers. (C) RNA-IP. MCF7 cells were transiently transfected with FLAG-TTP or FLAG-TTP^F118N^expression vector. A vector-only control was also included. After 24 h, cell lysates were isolated for immunoprecipitation using anti-FLAG M2 beads. RNA was extracted from the precipitated complexes for RT-PCR analysis using *EYA2* and *β*-*actin* primers.](ijbsv08p0606g08){#F6}
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